Ad. Santin et al., DEVELOPMENT AND CHARACTERIZATION OF AN IL-4-SECRETING HUMAN OVARIAN-CARCINOMA CELL-LINE, Gynecologic oncology, 58(2), 1995, pp. 230-239
Human ovarian carcinoma cell lines were genetically engineered to secr
ete the cytokine interleukin-4 (IL-4) by retroviral-mediated gene tran
sduction. These cells were transduced with the LXSN retroviral vector
containing the human IL-4 gene and the neomycin resistance selection m
arker. Numerous IL-4-secreting clones were isolated from different pap
illary serous carcinoma cell lines, including SKOV-3, UCI-101, and UCI
-107, and one clone derived from UCI-107 extensively characterized. Th
is clone, termed UCI 107E IL-4 GS, was shown to constitutively express
high levels of IL-4 (i.e., 900 to 1300 pg/ml/10(5) cells/48 hr) for o
ver 35 passages and 6 months of study. Like the parental cell line (UC
I-107), UCI 107E IL-4 GS cells expressed MHC class I and Her-2/neu sur
face antigens but did not express detectable MHC class II, ICAM 1, CA
125, or IL-4 receptors. No increase in expression of surface proteins
was noted between parental and UCI 107E IL-4 GS. The morphology of thi
s done did not differ from that of the parental or LXSN vector control
cells; however,parental cells had a faster growth rates than transduc
tants, UCI 107E IL-4 GS was sensitive to gamma irradiation since as li
ttle as 2500 rad killed most of the cells within 10 days of irradiatio
n, However, after irradiation, IL-4 secretion continued until about Da
y 8. The potential use of these IL-4-secreting ovarian carcinoma cells
as vaccines for woman with advanced ovarian cancer will be discussed.
(C) 1995 Academic Press, Inc.